Samsung Epis Holdings has opened its first biopharmaceutical research and development center in China focused on antibody-drug conjugates, or ADCs, joining a growing list of multinational drugmakers deepening their presence in a country that has become one of the world's most active hubs for cancer...
Liking and disliking news Highlights will help Daily News Highlights to understand visitor interests and top trends as per the user behavior hence this feature requires visitor to Sign In, if you are not registered yet, please Sing Up to personalize your reading.